FDA Inspection 1038967 — BrightGene Pharmaceutical Co., Ltd.
The FDA completed an inspection of BrightGene Pharmaceutical Co., Ltd. on Dec 8, 2017 in Suzhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Dec 8, 2017
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Suzhou (China)